广东溢多利生物科技股份有限公司 募集资金管理制度 第一章 总则 第一条 为完善广东溢多利生物科技技股份有限公司（以下简称"公司"） 治理，规范公司对募集资金的使用和管理，提高募集资金的使用效率和效益，维 护公司、股东、债权人及全体员工的合法权益，特制定本制度。 第二条 本制度制定依据：根据《中华人民共和国公司法》（以下简称"公 司法"）、《中华人民共和国证券法》（以下简称"证券法"）、《上市公司募集资 金监管规则》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称"创业板规范 指引"）等法律、行政法规、规范性文件及《广东溢多利生物科技股份有限公司 章程》（以下简称"公司章程"）的规定。 第三条 本制度所指"募集资金"是指公司通过发行股票或者其他具有股 权性质的证券，向投资者募集并用于特定用途的资金，不包括公司为实施股权激 励计划募集的资金。 第四条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新能力。中国证券监督管 ...

Core Viewpoint - The company reported a revenue of 415 million yuan for the first half of 2025, reflecting a year-on-year growth of 4.48%. However, net profit decreased by 66.50% to 13.997 million yuan. The company has decided not to distribute cash dividends, issue bonus shares, or increase capital from reserves [1]. Financial Performance - Revenue for the first half of 2025 reached 415 million yuan, marking a 4.48% increase compared to the previous year [1]. - Net profit for the same period was 13.997 million yuan, which represents a significant decline of 66.50% year-on-year [1]. Dividend Policy - The company announced that it will not distribute cash dividends, issue bonus shares, or utilize reserves for capital increase [1].

Financial Performance - The company's operating revenue for the first half of 2025 was CNY 415,009,616.63, representing a 4.48% increase compared to CNY 397,225,587.19 in the same period last year[25]. - The net profit attributable to shareholders decreased by 66.50% to CNY 13,996,955.96 from CNY 41,783,518.03 year-on-year[25]. - The basic earnings per share fell by 66.59% to CNY 0.0285 from CNY 0.0853 in the same period last year[25]. - The total revenue for the first half of 2025 reached 6,797 million yuan, representing a year-on-year increase of 3.31%[59]. - The company reported a net profit for the first half of 2025 of ¥14,566,878.09, a decrease of 65.3% from ¥41,915,429.60 in the same period last year[147]. - The total comprehensive income for the current period decreased by 147.21 million, resulting in a total of 2,609.46 million[161]. Cash Flow and Liquidity - The net cash flow from operating activities dropped significantly by 97.34%, amounting to CNY 1,391,054.04 compared to CNY 52,240,079.51 in the previous year[25]. - Cash flow from investment activities generated a net inflow of CNY 122,531,841.23 in the first half of 2025, compared to a net outflow of CNY 202,899,390.74 in the first half of 2024[151]. - The company reported a significant increase in cash and cash equivalents, with a net increase of 174.53% to $129.52 million from $47.18 million year-over-year[46]. - The total cash and cash equivalents at the end of the first half of 2025 reached CNY 410,252,453.73, up from CNY 299,241,241.36 at the end of the first half of 2024[151]. - The net increase in cash and cash equivalents for the first half of 2025 was CNY 49,515,572.77, contrasting with a decrease of CNY 88,412,246.75 in the first half of 2024[152]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,901,777,100.86, a decrease of 1.59% from CNY 2,948,587,167.07 at the end of the previous year[25]. - Total liabilities decreased from ¥294,388,193.40 to ¥271,040,009.01, a reduction of about 7.9%[140]. - Total equity decreased from ¥2,654,198,973.67 to ¥2,630,737,091.85, a decline of approximately 0.9%[140]. - The company reported a total of 100 million CNY credit limit from East Asia Bank Zhuhai Branch, with no borrowing amount at the end of the reporting period[115]. Research and Development - The company introduced 5 high-end talents to enhance operational efficiency and management effectiveness[34]. - The company is focused on developing high-value new products based on market demand in the synthetic biology sector[36]. - Research and development expenses were $47.47 million, a slight decrease of 2.48% from $48.68 million year-over-year[46]. - The company has committed to continuous R&D investment to enhance product competitiveness across various sectors, including animal nutrition and bioenergy[87]. Market Expansion and Strategy - The company has been expanding its overseas market presence, which may incur higher costs due to international political and economic instability[4]. - The company has established a marketing network covering over 60 countries and regions, with subsidiaries in Germany and Australia, enhancing international market presence[42]. - The company plans to expand its market presence through new product development and strategic partnerships in the upcoming quarters[59]. - The company is actively pursuing market expansion through strategic acquisitions and investments in new technologies[71]. Risks and Challenges - The company is facing risks related to macroeconomic conditions and industry competition, which may impact project timelines and expected economic benefits[6][7]. - The company faces risks related to macroeconomic conditions and industry fluctuations, particularly in the livestock sector, which could impact sales of its enzyme products[86]. Shareholder and Capital Management - The company plans not to distribute cash dividends or issue bonus shares[8]. - The company has a total of 100 million CNY credit limit from East Asia Bank Zhuhai Branch, with no borrowing amount at the end of the reporting period[115]. - The company has allocated 6.1 million for profit distribution to shareholders, maintaining the same level as the previous year[155]. - The company has reported a profit distribution of 3,230 million, which is a significant allocation to shareholders[164]. Corporate Governance and Compliance - The financial statements are prepared based on the accounting standards issued by the Ministry of Finance and comply with the disclosure rules set by the China Securities Regulatory Commission[168]. - The company’s financial reports are approved by the board of directors, ensuring compliance with relevant regulations[167]. - The company is included in the environmental information disclosure list with two subsidiaries, ensuring compliance with environmental reporting requirements[97].

Core Viewpoint - The market demand for polylactic acid (PLA) fiber is steadily increasing due to rising consumer awareness of environmental protection and a global pursuit of sustainable development. The market size in China is projected to reach approximately 4.511 billion yuan in 2024, with a year-on-year growth of 3.9%, and is expected to grow to 6.979 billion yuan by 2030 [1][20]. Industry Overview - PLA fiber is produced from starch-containing agricultural products such as corn and wheat, which are fermented to generate lactic acid, then polymerized and spun into fibers. It is a biodegradable synthetic fiber that can decompose into carbon dioxide and water in the environment [4][16]. - The fiber has excellent properties such as good hand feel, UV resistance, low flammability, and excellent processing performance, making it suitable for various applications including fashion, sportswear, and hygiene products [6][7]. Market Size and Growth - The PLA fiber industry in China is expected to maintain strong growth momentum, with the market size projected to reach approximately 6.979 billion yuan by 2030 [1][20]. - The market demand for PLA fiber will continue to expand due to increasing consumer environmental awareness and ongoing government support for the environmental industry [20]. Production Process - The production of PLA fiber involves extracting starch from biomass materials, fermenting it to produce lactic acid, and then polymerizing it into PLA, which is subsequently spun into fibers [8][10]. Industry Development History - The research and development of PLA fiber have a history of over half a century, with significant advancements made by various companies in the field, including those in China [12][22]. Industry Chain - The PLA fiber industry chain includes upstream raw materials (corn, wheat, etc.), midstream production processes, and downstream applications in textiles, medical devices, and packaging [14][16]. Key Companies - Major companies in the PLA fiber industry include Anhui Fengyuan Group, Ma'anshan Tongjie Liang Biological Materials Co., Ltd., and Zhejiang Haizheng Biological Materials Co., Ltd., among others [2][22][24]. Industry Trends - The PLA fiber industry is moving towards high performance, with a focus on enhancing heat resistance, mechanical strength, and functional properties through molecular structure modification and composite processing technologies [29]. - The application of PLA fiber is diversifying beyond textiles to include biodegradable wipes, medical dressings, and packaging materials, driven by the deepening "plastic ban" policies [30][31].

Group 1 - The core viewpoint of the news is that Yiduoli's recent financial performance shows a decline in net profit despite a slight increase in total revenue, indicating potential challenges for the company [1][3] - As of August 5, 2025, Yiduoli's stock price closed at 7.91 yuan, down 0.63%, with a turnover rate of 2.44% and a trading volume of 119,600 hands, amounting to 95 million yuan in transaction value [1] - The company's latest quarterly report indicates total revenue of 202 million yuan, a year-on-year increase of 1.79%, while net profit attributable to shareholders decreased by 75.19% to 4.87 million yuan [1] Group 2 - Yiduoli has made investments in 13 companies and participated in 25 bidding projects, showcasing its active engagement in the market [2] - The company holds 85 trademark registrations and 109 patents, indicating a strong focus on intellectual property [2] - Yiduoli has obtained 72 administrative licenses, reflecting its compliance and operational capabilities within the industry [2]

Core Viewpoint - The company, Yiduoli, announced on July 31 that it will engage in securities investment using idle self-owned funds, which will not affect the normal operations of the company and its subsidiaries [1] Group 1 - The company will prioritize investments in new stock placements or subscriptions to minimize operational risks [1] - The decision-making and execution procedures for the securities investment are detailed in the company's "Securities Investment Management System" [1]

Core Viewpoint - The company Yiduoli (300381) reported that as of July 18, 2025, the total number of shareholders is 21,304 [1] Summary by Relevant Sections - Company Information - Yiduoli has a total of 21,304 shareholders as of the specified date [1]

广东溢多利生物科技股份有限公司 证券投资管理制度 第一章 总则 第一条 为规范广东溢多利生物科技股份有限公司（以下简称"公司"）的 证券投资行为，建立完善有序的投资决策管理机制，有效防范投资风险，强化 风险控制，保证公司资金、财产安全，维护投资者和公司合法权益，根据《中 华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票 上市规则》等法律法规和《广东溢多利生物科技股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，结合公司的实际情况，制定本制度。 第二条 本制度所称证券投资，是指公司在法律法规规定允许的情况下， 在控制投资风险的前提下，以提高资金使用效率和收益最大化为原则，在境内 外证券市场投资证券、衍生品的行为，包括新股配售或者申购、证券回购、股 票及存托凭证投资、债券投资以及深圳证券交易所认定的其他投资行为。 以下情形不适用本制度： （一）固定收益类或者承诺保本的投资行为； （二）参与其他上市公司的配股或者行使优先认购权利； （三）购买其他上市公司股份超过总股本的 10%，且拟持有三年以上的证 券投资； （四）公司首次公开发行股票并上市前已进行的投资。 第三条 本制度适用于公司 ...

股票代码：300381 股票简称：溢多利 公告编号：2025-036 广东溢多利生物科技股份有限公司 重要内容提示： 1．投资种类：广东溢多利生物科技股份有限公司（以下简称"公司"）及 控股子公司拟使用自有资金开展证券投资的种类包括新股配售或者申购、证券 回购、股票及存托凭证投资、债券投资以及深圳证券交易所认定的其他投资产 品。 2．投资金额：公司及控股子公司拟使用不超过人民币 3,000 万元（含本 数）自有资金开展证券投资，在上述额度内，资金可以滚动使用，但期限内任 一时点的交易金额（含前述投资的收益进行再投资的相关金额）不得超过上述 额度。 3．特别风险提示：公司及控股子公司进行证券投资可能面临的风险包括 但不限于市场风险、流动性风险、操作风险等，公司将积极落实内部控制制度 和风险防范措施，审慎进行证券投资，敬请投资者充分关注投资风险。 一、投资情况概述 1．投资目的：为提高自有资金使用效率、增加股东回报，在充分保障公 司及控股子公司日常经营的资金需求并有效控制风险的前提下，公司及控股子 公司将使用闲置自有资金开展证券投资，增加资金收益。 关于使用闲置自有资金开展证券投资的公告 本公司及董事会全体成员保 ...

一、董事会会议召开情况 广东溢多利生物科技股份有限公司（以下简称"公司"）第八届董事会第 十二次会议于 2025 年 7 月 28 日在公司会议中心以现场和通讯相结合的方式 召开。会议通知于 2025 年 7 月 17 日以信息、邮件等方式发送至公司全体董 事。会议应出席董事 7 名，实际出席会议董事 7 名，公司监事、部分高级管理 人员列席了本次会议。会议由董事长陈少美先生主持。本次会议符合《公司法》 和《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 本次会议以投票表决方式审议通过了如下议案： 股票代码：300381 股票简称：溢多利 公告编号：2025-035 广东溢多利生物科技股份有限公司 第八届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 范投资风险，强化风险控制，保证公司资金、财产安全，维护投资者和公司合 法权益，董事会根据《中华人民共和国证券法》《深圳证券交易所创业板股票 上市规则》等法律法规《公司章程》的有关规定，结合公司的实际情况，制定 了《证券投资管理制度》，具体内容详见公司在巨潮资讯网(www. ...